How did Theravance's revenue and expenses trend in Q4 2024?

Theravance's revenue and expenses in Q4 2024 showed a notable revenue figure with a corresponding R&D and other expenses, indicating active business operations and investment in development. 1. **Revenue Trend**: Theravance's revenue for Q4 2024 was $64.38 million. This figure underscores the company's successful collaboration with Viatris, which has contributed significantly to its revenue stream. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |TBPH|TBPH.O|Theravance|20240101-2024|Viatris Collaboration Agreement|6.4381E7|185| |TBPH|TBPH.O|Theravance|20240101-2024|Viatris Collaboration Agreement|4.5627E7|185| |TBPH|TBPH.O|Theravance|20240101-2024|Viatris Collaboration Agreement|2.8759E7|185| |TBPH|TBPH.O|Theravance|20240101-2024|Viatris Collaboration Agreement|1.4503E7|185| |TBPH|TBPH.O|Theravance|20240101-2024|Viatris Collaboration Agreement|1.4503E7|185| |code|Ticker|Name|Date|Total Other Expenses|R&D Expenses|market_code| |---|---|---|---|---|---|---| |TBPH|TBPH.O|Theravance|2024 Q1||8968000|185| |TBPH|TBPH.O|Theravance|2024 Q2||9954000|185| |TBPH|TBPH.O|Theravance|2024 Q3||9268000|185| |TBPH|TBPH.O|Theravance|2024 Q4||9453000|185| 2. **Expense Trend**: The total other expenses for the quarter were $9.45 million. This indicates that Theravance is also investing in areas outside of its core business, which could include administrative costs, legal fees, or other operational expenses. The R&D expenses, although not provided a specific figure, are a critical component of Theravance's strategy, reflecting its commitment to innovation and product development. 3. **Insights**: The presence of both revenue and significant expenses suggests that Theravance is in an active phase of business operations and product development. The absence of other revenue streams beyond the collaboration with Viatris highlights the importance of this partnership in generating income for the company. The R&D expenses, while not quantified in the provided data, are likely a substantial portion of the company's overall expenses, underscoring its focus on advancing its pipeline and bringing new products to market.